Top Tweets for #EnterO
๐ #PGIL (9.6%)
๐ #IMAGICAA (8.0%)
๐ #ICIL (8.0%)
๐ #JSWINFRA (7.6%)
๐ #PATELENG (7.6%)
๐ #KPRMILL (7.4%)
๐ #ENTERO (6.8%)
#StocksInFocus #NIFTY #NSE #BSE #StocksToTrade #StocksToWatch #StocksMarket
#FY26 Aggregate Revenue of #PharmaDistribution co.s was ~โน21.7K Cr., +20% YoY
Aggregate EBITDA Margin expanded to ~4.1%, +165bps YoY
Highest Growth YoY:
โข Revenue: #Zota
โข EBITDA: #Entero
โข EBITDA Margin: #Medplus
Perpetuity Funds (SEBI Registration No- IN/AIF3/17-18/0508)
Perpetuity Angel Fund (SEBI Registration No- IN/AIF1/26-27/2120)
For information purposes only, not investment advice
#Health2Wealthย #Perpetuity
Entero Healthcare Q4FY26 Deep Dive
#EnteroHealthcare #ENTERO
Entero Healthcare reported a strong Q4FY26, but this is not a simple โrevenue up, EBITDA up, PAT upโ story. The real question is whether Entero is slowly evolving from a low-margin pharma distributor into a higher-margin healthcare distribution platform, or whether it remains a complicated, acquisition-led distribution roll-up.
Q4 revenue grew 42.6% YoY to โน1,910 cr. The growth mix was important: organic growth was ~17%, and acquisition-led growth contributed ~26%. For FY26, revenue grew 29.3% to โน6,591 cr. Entero continues to grow faster than the Indian Pharma Market, but the outperformance multiplier has moderated. Management clarified that underlying like-for-like organic growth is still around 15%, or roughly 1.5x industry growth, but reported growth is affected by some businesses moving to net-margin accounting and the conscious exit from some low-margin / low-ROIC revenue.
The most important operating metric this quarter was gross margin. Q4 gross margin expanded to 10.9%, up around 110 bps YoY, while FY26 gross margin improved to 10.3%, up around 78 bps YoY. For a distributor, this is meaningful. Management attributed this to two factors: procurement benefits from scale and a higher contribution from commercial distribution roles, including demand generation. Management said 10โ15% of sales currently comes from such full commercial roles, and margins in these contracts can be at least double normal distribution margins. That said, I think the main reason for margin improvement is likely product mix, because MedTech carries much higher gross margins than pharmaceutical distribution.
This is the crux of the thesis. Plain pharma distribution is not a very exciting business. It is low margin, working-capital heavy and does not usually have much pricing power. But if Entero can steadily increase the share of higher-margin commercial distribution, MedTech, diagnostics, cold-chain and value-added manufacturer partnerships, then the business starts looking less like a plain distributor and more like a scaled healthcare distribution platform.
MedTech has become quite meaningful to this story. Entero closed 7 acquisitions in FY26, including 3 in MedTech. Management said MedTech is already 15%+ of revenue and can move towards 20% over the next 2โ3 years. FY27 MedTech revenue should cross โน1,000 cr based on the current platform itself. This is important because MedTech carries better margins than pharma distribution, especially where Entero plays a commercial role. But it also makes the business more complex. In IVD, for example, Entero places machines at labs under reagent-rental type models. This creates sticky revenue, but also increases depreciation. So EBITDA margin improvement is good, but investors need to track depreciation, finance cost, minority interest and owner earnings carefully.
EBITDA performance was strong. Q4 EBITDA grew 76% YoY to โน86 cr, and EBITDA margin expanded to 4.5% versus 3.7% YoY. FY26 EBITDA grew 55% to โน266 cr, with EBITDA margin improving to 4.0%. Management has guided for 5.0% EBITDA margin in FY27, which means they expect another ~100 bps margin expansion. The bridge is higher MedTech mix, gross margin improvement, procurement benefits, operating leverage, exit from low-margin business and more commercial distribution contracts. This is ambitious, but not impossible if the mix shift continues.
The biggest issue in Q4 was NCI / minority interest. Consolidated PAT grew 44% YoY to โน45 cr, but PAT attributable to owners was only โน28 cr, up just 9% YoY. That is a very big difference. For shareholders, owner PAT matters more than consolidated PAT. Management explained that one partly owned subsidiary had an abnormally strong quarter, which led to minority interest being almost 38% of PAT in Q4. They expect NCI to normalize to 25โ27% of pre-NCI PAT in FY27. This clarification was important, but honestly, it should have been part of the opening remarks. If consolidated PAT is +44% but owner PAT is only +9%, management should proactively explain why.
This is part of a broader communication issue. I like the company and the operating direction, but communication could be sharper. The NCI issue was clarified only after an analyst asked. The flattish net worth issue was also clarified only after a question, with the CFO explaining that it was due to first-time recognition of put-option liabilities for subsidiaries where Entero is not a 100% shareholder. Similarly, the FY27 revenue growth guidance initially looked low given the FY26 acquisitions, but management later clarified that it includes some businesses being recognized on a net-margin basis and conscious exit from low-margin / low-ROIC business. These are important points and should ideally be explained upfront because the business is becoming more complex.
Cash flow was the biggest positive in FY26. FY25 operating cash flow was negative โน77 cr. FY26 operating cash flow turned positive to โน96 cr. Q4 alone generated โน105 cr of operating cash flow. Net working-capital days improved to 59 days in Q4 versus 64 days QoQ and 66 days YoY. For a distributor, this is extremely important. Revenue growth without cash conversion is low-quality growth. Management has guided for FY27 operating cash flow conversion of at least 50% of EBITDA. Given FY27 EBITDA guidance of roughly โน405 cr, this implies OCF of โน200 cr+ if delivered. This will be one of the most important monitorables.
Managementโs working-capital explanation was also interesting. Q4 revenue was already โน1,910 cr, which annualizes to roughly โน7,600โ8,000 cr. FY27 revenue guidance is around โน8,100 cr. So management is saying most of the working capital required for FY27 revenue is already sitting in the March balance sheet, and incremental working capital requirement should not be very high unless growth is much higher than guidance. This makes sense, but it has to show up in FY27 cash flow.
FY27 guidance is clear: 23% revenue growth, 5% EBITDA margin, at least 50% EBITDA-to-OCF conversion, and no new acquisitions included. On FY26 revenue of โน6,591 cr, 23% growth implies FY27 revenue of around โน8,100 cr. At 5% EBITDA margin, that implies EBITDA of around โน405 cr. Assuming D&A of ~โน60 cr, gross finance cost of ~โน80 cr, some other income / interest income, 22โ23% tax rate and NCI at 25โ27% of pre-NCI PAT, I get rough FY27 PAT attributable to owners of around โน155โ160 cr, or EPS of roughly โน35โ37 after NCI. This is my estimate, not company guidance.
At a market cap of around โน5,200 cr, the stock trades at roughly 45x FY26 owner PAT of โน115 cr. On rough FY27 owner PAT of โน155โ160 cr, the stock trades at around 33x FY27E earnings. So valuation is neither cheap nor crazy. It is reasonable only if Entero delivers 5% EBITDA margin, โน200 cr+ OCF, and clean owner-level earnings growth.
The bull case is that Entero is building a scaled healthcare distribution platform: 1 lakh+ pharmacies, 3,600+ hospitals, 97,500+ SKUs, 3,300+ manufacturers, 136 warehouses and presence across 523 districts. Manufacturers come to Entero because it has customers. Customers come to Entero because it has product breadth. This two-sided network has value. Scale, procurement, cold-chain, SKU breadth and commercial distribution relationships matter.
But I would not over-romanticize the moat. Simply moving boxes is not a great business. The moat improves only if higher-margin commercial distribution and MedTech keep scaling, and if cash conversion improves. Otherwise, this can become a complicated roll-up with rising goodwill, NCI leakage, put-option liabilities and owner PAT diverging from consolidated PAT.
My view: decent company, good quarter, right strategic direction. Gross margin expansion and cash flow improvement were the biggest positives. The main concerns are owner PAT quality and communication around NCI, put-option liabilities and guidance adjustments. At around 33x FY27E owner PAT, valuation is neither cheap nor crazy. If the company can sustain mid-teens organic growth, improve margins, convert EBITDA into cash, and keep scaling MedTech/commercial distribution, it could become an attractive long-term healthcare distribution platform. But FY27 execution and communication quality will matter a lot from here.
Entero Healthcare Solu L Q4 FY26 -
Revenue rises to 1,909.93Cr compared to 1,706.52Cr (QoQ)
PBT rises to 57.95Cr compared to 40.4Cr (QoQ)
PAT rises to 45.13Cr compared to 33.88Cr (QoQ)
#ENTERO
#Q4FY26 Mainboard #results on 25th May -
Blockbuster Set โ
Hitachi Energy (#PowerIndia )
Divgi Torq (#Divgiitts )
Sudarshan Chem (#SudrasChem )
INA (#INA )
Ajmera Realty (#Ajmera )
Solid Set -
Uniparts India (#Uniparts ) - Good numbers after a long time
Entero Health (#Entero )
KSH Intl (#KSHIntl )
String Metaverse (#Meta )
Awfis Space (#AWFIS )
Narmada Gelatine (#ShawGeltin )
Suzlon (#Suzlon )
Shriram Prop (#ShriramPps )
Crizac (#Crizac )
Sundaram Brake (#SundrmBrak )
Pace Digitek (#PaceDigitk )
Good/Decent Set โ
IFB Inds (#IFBInd )
Travel Food (#TravelFood ) - Down QoQ
Pasupati Arcylon (#Pasuptac ) - Solid Yoy, down Qoq
Amara Raja (#AmaraRaja )
Suprajit Engg (#Suprajit )
Fredun Pharma (#Fredun )
Suryalata Spg (#Suryala )
Syschem (India) (#Syschem )
Steel Excahnge (#SteelxInd ) -Rev down, solid margin Exp
Indo Rama Synthetic (#IndoRama )
Century Extrusion (#CentExt )
Career Point (#CPEdu ) - Rev Down, Margins Expand
Modern Malleable (#ModMa )
Bhatia Communication (#Bhatia )
Campus Activewear (#Campus )
Kanoria (#KanoriChem ) - Rev down, margins exp
Saksoft (#SakSoft )
Zodiac Energy (#Zodiac )
NILE (#Nile )
Tembo Global (#Tembo )
Yatharth Hospital (#Yatharth )
Omnitech Engg (#Onmi )
Belrise (#Belrise )
Turnaround โ
Sigma Advanced (#SigmaAdv )
Eyantra Ventures (#EY )
Pine Labs (#PineLabs ) - Good YoY, down QoQ
Chemplast Sanmar (#Chemplasts )
Correcting my #ENTERO tweet โ OCF is Rs. 96 Cr not Rs. 6 Cr. My bad. Full decode below. ๐
FY26 โ guided 3, delivered 3 โ
Revenue: Rs. 6,591 Cr +29% ๐. Q4 +43% โ best quarter yet ๐
Organic: 13.4% YoY. 1.6x IPM growth ๐
EBITDA: 3.4% โ 4.0%. Q4 hits 4.5% ๐ช
Gross margin: 9.5% โ 10.3% (+78bps) โ
OCF swings Rs. 173 Cr: -77 โ +96 Cr ๐ข
WC drag halved. 7 acquisitions absorbed. ROCE: 10.7% โ 14.6% ๐
MedTech: 3 acquisitions in IVD + Cardiology. FY27 target Rs. 1,000 Cr revenue. Margin accretive. The real story for FY28+. ๐ฅ
And they kept buying โ two more today. Vishal Surgicals + Vishal Surgicals & Medicals. 51 total since inception. ๐บ๏ธ
FY27 guidance: +23% revenue, 5% EBITDA, 50% OCF/EBITDA conversion โ thatโs ~Rs. 200 Cr OCF targeted ๐ฏ
Valuation: ~15x FY27E EV/EBITDA vs sector at 20-25x ๐ฐ
The tailwind nobodyโs talking about: Apollo Healthtech (Keimed + Apollo HealthCo) listing by Q4FY27. Shareholder vote June 24 this month. When Indiaโs largest pharma distributor gets a listed benchmark, Enteroโs re-rating case gets much stronger. ๐ฏ
Invested. Not investment advice. DYOR. ๐
#ENTERO FY26 Full Year Results ๐ฅ
Q4 revenue +43% YoY. Rs. 6,591 Cr for the full year.
+29% over FY25. ๐
But here's the real story.
FY25 OCF: -Rs. 77 Cr ๐ด
FY26 OCF: +Rs. 6 Cr ๐ข
First positive operating cash flow. The WC drag is finally turning. Distribution businesses live and die by cash conversion - this inflection matters more than the headline growth. ๐ก
PAT to owners: Rs. 115 Cr. +21% YoY. Clean print, one-off labour code charge stripped out. โ
The acquisitions don't stop ๐ - two more tuck-in acquisitions announced today. Vishal Surgicals and Vishal Surgicals & Medicals, both Telangana-based pharma distributors. Combined turnover ~Rs. 17 Cr.
Small individually, consistent with the infill strategy. ๐บ๏ธ
50+ subsidiaries now. Rs. 6,591 Cr revenue. The network is being built. ๐๏ธ
Watch for FY27: does OCF hold positive as new acquisitions add fresh WC pressure? That's the test.
(Not investment advice. DYOR.) ๐
#ENTERO
#NSE
๐จ #Q4FY26 Results Update | 25/05/26 | 9:00 PM ๐จ
๐ข Entero Healthcare
#Entero #EnteroHealth
๐ฅ Excellent Q4FY26 | Strong across all parameters
โ
EBITDA growth +76%
โ
Best margins ever reported
โ
Highest-ever Revenue, EBITDA, PBT & PAT in company history
โ
Strong QoQ + YoY improvement
โ
Positive operating cash flow as per guidance
๐ Revenue: โน1910 Cr vs โน1339 Cr (+42.6% YoY) | Q3: โน1706 Cr (+12.0% QoQ)
๐ EBITDA: โน86 Cr vs โน48 Cr (+79.2% YoY) | Q3: โน68 Cr (+26.5% QoQ)
๐ PBT: โน58 Cr vs โน37 Cr (+56.8% YoY) | Q3: โน40 Cr (+45.0% QoQ)
๐ PAT: โน45 Cr vs โน31 Cr (+45.2% YoY) | Q3: โน34 Cr (+32.4% QoQ)
๐ OCF: โน96 Cr vs -โน77 Cr โ
โโโโโโโโโโโโโโโโโโ
๐ข Harrisons Malayalam
#HarrMalaya
๐ฅ Good Q4FY26 with steady improvement
โ
Positive QoQ + YoY growth
โ
Profitability improving gradually
โ
Healthy cash flow maintained
๐ Revenue: โน147 Cr vs โน136 Cr (+8.1% YoY) | Q3: โน141 Cr (+4.3% QoQ)
๐ PBT: โน9 Cr vs โน5 Cr (+80.0% YoY) | Q3: โน6.6 Cr (+36.4% QoQ)
๐ PAT: โน7.5 Cr vs โน4.5 Cr (+66.7% YoY) | Q3: โน6 Cr (+25.0% QoQ)
๐ OCF: โน25 Cr vs โน23 Cr (+8.7% YoY)
โโโโโโโโโโโโโโโโโโ
๐ข Travel Food Services
#TFS #TravelFood
๐ฅ Good Q4FY26 performance
โ
Strong revenue growth
โ ๏ธ Slight margin compression QoQ
โ ๏ธ PBT & PAT softer sequentially
โ
Strong cash generation continues
๐ Revenue: โน461 Cr vs โน366 Cr (+25.9% YoY) | Q3: โน456 Cr (+1.1% QoQ)
๐ PBT: โน162 Cr vs โน134 Cr (+20.9% YoY) | Q3: โน176 Cr (-8.0% QoQ)
๐ PAT: โน122 Cr vs โน106 Cr (+15.1% YoY) | Q3: โน136 Cr (-10.3% QoQ)
๐ OCF: โน392 Cr vs โน515 Cr (-23.9% YoY)
โโโโโโโโโโโโโโโโโโ
๐ก Cian Agro
#CianAgro
โ ๏ธ Result format difficult to decode
โ
Strong YoY growth visible
โ Sequential softness seen in some parameters
๐ Revenue: โน656 Cr (+34% YoY)
๐ PBT: โน62 Cr vs โน12 Cr (+416.7% YoY) | Q3: โน114 Cr (-45.6% QoQ)
โโโโโโโโโโโโโโโโโโ
๐ก Kalyani Forge
#KalyaniForge
โ ๏ธ Revenue under pressure
โ
Profit supported by other income
โ ๏ธ Operating cash flow lower QoQ
๐ Revenue: โน57 Cr vs โน59 Cr (-3.4% YoY) | Q3: โน58 Cr (-1.7% QoQ)
๐ Other Income: โน2 Cr vs โน0.3 Cr (+566.7% YoY)
๐ PBT: โน6 Cr vs โน3 Cr (+100% YoY) | Q3: โน4 Cr (+50% QoQ)
๐ OCF: โน7 Cr vs โน22 Cr (-68.2% YoY)
โโโโโโโโโโโโโโโโโโ
Overall View:
๐ข Strongest Print: Entero Healthcare
๐ข Stable Improvement: Harrisons Malayalam
๐ข Good Growth: Travel Food Services
๐ก Mixed: Cian Agro
๐ก Profit improved but revenue weak: Kalyani Forge
Follow for quality market insights & Swing Blaster setups ๐
Entero Healthcare Solutions Q4FY26 Results:-
#Q4FY26 #Stockmarket #Nifty #Entero
โค FY27 Guidance
โ Revenue growth 23.0% YoY
โ EBITDA margin 5.0%
โ Operating cash flow to EBITDA conversion ratio 50.0%
โค FY26 guidance was fully achieved
โ Revenue growth guidance 30.0% vs actual 31.5%
โ EBITDA margin guidance 4.0% achieved at 4.0%
โ Operating cash flow guidance โน100 Cr vs actual โน96 Cr
Entero Healthcare Solutions Ltd Q4FY26 Results:-
#Q4Results #Q4FY26 #Stockmarket #Nifty #Entero
Revenue 1909.93 Cr vs 1339.06 Cr
(+42.63% YoYโ+11.92% QoQ)
EBITDA 86.04 Cr vs 48.92 Cr
(+75.90% YoY โ+26.95% QoQ)
EBITDA Margin 4.50% vs 3.65% YoY & 3.97% QoQ
PBT Ex-Exceptional Items 57.95 Cr vs 37.23 Cr
(+55.67% YoYโ+19.29% QoQ)
PAT 45.13 Cr vs 31.42 Cr
(+43.62% YoYโ+33.21% QoQ)
PAT After Minority interest 28.01 Cr vs 25.69 Cr
(+9.04% YoYโ+1.36% QoQ)
Other Income 4.01 Cr vs 7.29 Cr YoY & 4.61 Cr QoQ
Last Q3 Exceptional loss of 8.18 Cr
Good results by #enterohealthcare #entero .
Just like in the developed economies like the US and Germany, healthcare distribution business model needs scale to prove itself.
Entero seems to be on that path now.
First year of positive cash flow from operations after years of negative. Revenue and profitability up handsomely.
Lesson for equity analysts: Follow the themes that have worked in the developed world. What has worked there will likely work overtime in emerging markets like India.
Watch here:
https://t.co/HEGn4CzWVI
#investandrise #emergingmarkets #equityresearch #valuation #fundamentalanalysis #financialmodeling.
Earlier this year, I published a video breaking down how I analyse and value a business โ using Entero Healthcare ๐ฅ๐ as a live case study.
The goal isnโt to recommend a stock.
Itโs to demonstrate a ๐๐๐ฟ๐๐ฐ๐๐๐ฟ๐ฒ๐ฑ ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐ฎ๐ฐ๐ต to equity research :
๐ญ. ๐๐ป๐ฑ๐๐๐๐ฟ๐ (Healthcare Distribution): India is ~90% fragmented, while the US is ~92% consolidated. Itโs like looking at the US market 50 years agoโthe consolidation opportunity is massive.
๐ฎ. ๐๐๐๐ถ๐ป๐ฒ๐๐ ๐ ๐ผ๐ฑ๐ฒ๐น: How Entero acts as an "acquisition engine" by rolling up local distributors, and what actually needs to go right for it to work.
๐ฏ. ๐๐๐ป๐ฑ๐ฎ๐บ๐ฒ๐ป๐๐ฎ๐น๐: Why healthcare distro is a low-margin, high-volume, high capital-turn business, and how working capital stress impacts cash flows.
๐ฐ. ๐ ๐ผ๐ฎ๐ ๐๐๐๐ฒ๐๐๐บ๐ฒ๐ป๐: Evaluating their footprint across 20 states and ~85,000 SKUs to assess business moat
๐ฑ. ๐๐ฒ๐ ๐ฅ๐ถ๐๐ธ๐: Integration execution, cash flow quality, and audit remarks that are easy to miss but matter disproportionately.
๐ฒ. ๐ฉ๐ฎ๐น๐๐ฎ๐๐ถ๐ผ๐ป: Putting it all together to arrive at a realistic value and compare with global peers
If you're trying to ๐น๐ฒ๐ฎ๐ฟ๐ป ๐ต๐ผ๐ ๐๐ผ ๐๐ต๐ถ๐ป๐ธ ๐น๐ถ๐ธ๐ฒ ๐ฎ๐ป ๐ฒ๐พ๐๐ถ๐๐ ๐ฎ๐ป๐ฎ๐น๐๐๐ / strategy consultant, this might be worth your time.
๐ฅ Watch here
https://t.co/qB79jT7pIP
#Investing #EquityResearch #Valuation #investandrise #financialmodeling #emergingmarkets #mentoring #financialstatementanalysis #healthcare #healthcaredistribution #EnteroHealthcare
#ENTERO FY26 Full Year Results ๐ฅ
Q4 revenue +43% YoY. Rs. 6,591 Cr for the full year.
+29% over FY25. ๐
But here's the real story.
FY25 OCF: -Rs. 77 Cr ๐ด
FY26 OCF: +Rs. 6 Cr ๐ข
First positive operating cash flow. The WC drag is finally turning. Distribution businesses live and die by cash conversion - this inflection matters more than the headline growth. ๐ก
PAT to owners: Rs. 115 Cr. +21% YoY. Clean print, one-off labour code charge stripped out. โ
The acquisitions don't stop ๐ - two more tuck-in acquisitions announced today. Vishal Surgicals and Vishal Surgicals & Medicals, both Telangana-based pharma distributors. Combined turnover ~Rs. 17 Cr.
Small individually, consistent with the infill strategy. ๐บ๏ธ
50+ subsidiaries now. Rs. 6,591 Cr revenue. The network is being built. ๐๏ธ
Watch for FY27: does OCF hold positive as new acquisitions add fresh WC pressure? That's the test.
(Not investment advice. DYOR.) ๐
#ENTERO
#NSE
#Entero - Entero Healthcare Solutions Ltd quarterly result - Good numbers
Entero Healthcare Solutions Ltd Q4FY26 Results:-
#Q4Results #Q4FY26 #Stockmarket #Nifty #Entero
Revenue 1909.93 Cr vs 1339.06 Cr
(+42.63% YoYโ+11.92% QoQ)
EBITDA 86.04 Cr vs 48.92 Cr
(+75.90% YoY โ+26.95% QoQ)
EBITDA Margin 4.50% vs 3.65% YoY & 3.97% QoQ
PBT Ex-Exceptional Items 57.95 Cr vs 37.23 Cr
(+55.67% YoYโ+19.29% QoQ)
PAT 45.13 Cr vs 31.42 Cr
(+43.62% YoYโ+33.21% QoQ)
PAT After Minority interest 28.01 Cr vs 25.69 Cr
(+9.04% YoYโ+1.36% QoQ)
Other Income 4.01 Cr vs 7.29 Cr YoY & 4.61 Cr QoQ
Last Q3 Exceptional loss of 8.18 Cr
Can #Entero Healthcare meet the guidance? If yes, I think it will be a big positive. What will be your targets in both missing and achieving them?
๐
Tomorrow's Earnings Calendar - 25 May, 2026
Key companies reporting results:
#POWERINDIA
#SUZLON
#RVNL
#CONCOR
#NBCC
#PINELABS
#POLYMED
#TECHNOE
#ARE_M
#TRAVELFOOD
#NESCO
#YATHARTH
#ABFRL
#SUDARSCHEM
#BLUEJET
#CAMPUS
#AARTIPHARM
#SIGMAADV
#SUPRAJIT
#ENTERO
#NIRLON
#OMNI
#TVSSCS
#SURYAROSNI
#KSHINTL
#MANINDS
#CIANAGRO
#IFBIND
#PACEDIGITK
#GUJTHEM
#CHEMPLASTS
#HEIDELBERG
#ORCHPHARMA
#CRIZAC
#INA
#JINDWORLD
#UNIPARTS
#FMGOETZE
#DDEVPLSTIK
#AWFIS
#StocksToWatch #EarningsCalendar
#ENTERO 3X POSSIBLE
Top 04 Best Swing Stocks for Tomorrow ๐
- 10-15% Upside Potential in Swing Basis for next three days.
Save it for Later ๐
#Entero
#POLICYBZR
#SGMART
#RAYMONDREL
Last Seen Hashtags on Sotwe
TEZOSTUESDAY
asian onlyfans video
Seen from United States
turbanliifลa
Seen from Turkey
morrita
Seen from United States
เธฃเธฑเธเธเธฒเธเธฃเธฑเธเธชเธดเธ
Seen from Thailand
ใตใใพใกใขใฐใช
Seen from United States
26thHBDFIRSTONE
Seen from United Kingdom
omegle
Seen from Turkey
่ฟทไบบ็cui
Seen from United States
ometv jilbab
Seen from Indonesia
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.9M followers
Taylor Swift
@taylorswift13
82.8M followers
Lady Gaga
@ladygaga
74.2M followers
Virat Kohli
@imvkohli
71.7M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.6M followers
Bill Gates
@billgates
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
61.9M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers